Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)

Trends Endocrinol Metab. 2020 Aug;31(8):570-579. doi: 10.1016/j.tem.2020.04.003. Epub 2020 May 15.


It is well known that myo-inositol (MI) and D-chiro-inositol (DCI) are insulin-sensitizing agents, and MI is of proven utility in polycystic ovary syndrome (PCOS). In addition, MI plays a pivotal role in the physiology of reproduction, and has beneficial effects on the development of oocytes, spermatozoa, and embryos. By contrast, DCI has little effect on spermatozoa, but high concentrations in the ovary can negatively affect the quality of oocytes and the blastocyst. Overall, the evidence in the literature supports the beneficial effects of MI in both female and male reproduction, warranting clinical use of MI in assisted reproductive treatment (ART).

Keywords: D-chiro-inositol, polycystic ovary syndrome; assisted reproductive treatment; in vitro fertilization; infertility; myo-inositol.

Publication types

  • Review

MeSH terms

  • Female
  • Fertilization in Vitro / methods
  • Humans
  • Inositol / therapeutic use*
  • Male
  • Polycystic Ovary Syndrome / drug therapy
  • Reproductive Techniques, Assisted*


  • Inositol